The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …

The interferons (IFNs) are a family of cytokines that protect against disease by direct effects
on target cells and by activating immune responses. The production and actions of IFNs are …

Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this
Review, we discuss accumulating evidence indicating that type I IFNs produced by …

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

The quest for treatment-free remission (TFR) and deep molecular response (DMR) in
chronic myeloid leukemia (CML) has been profoundly impacted by tyrosine kinase inhibitors …

The interferons (IFNs) are glycoproteins with strong antiviral activities that represent one of
the first lines of host defense against invading pathogens. These proteins are classified into …

Purpose Deep molecular response (MR4. 5) defines a subgroup of patients with chronic
myeloid leukemia (CML) who may stay in unmaintained remission after treatment …

Type I interferons (IFN-I) have long been heralded as key contributors to effective antiviral
responses. More widely understood in the context of acute viral infection, the role of this …

Every year, more than 8000 new cases of chronic myeloid leukemia (CML) are diagnosed in
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …

The first report on the antitumor effects of interferon α/β (IFN-I) in mice was published 50
years ago. IFN-α were the first immunotherapeutic drugs approved by the FDA for clinical …